openPR Logo
Press release

Operationally on track, Süd-Chemie on target

10-31-2011 02:05 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Clariant International Ltd

/ PR Agency: EMG
Solid operational performance with differentiated demand picture from business to business, strong headwind from currencies; Catalysis & Energy with the expected pick-up in sales.
Q3 sales up 25% in local currency and 9% in Swiss francs, driven by acquisitions and higher sales prices.

Q3 EBITDA before exceptional items at CHF 216 million, down from CHF 232 million in the previous-year period, negative currency impact of CHF 73 million.

Q3 EBITDA margin before exceptional items reached 11.6% compared to 13.6% a year ago; 13.4% at constant currencies Q3 cash flow from operations turned positive at CHF 105 million compared to CHF –101 million in Q2 2011 and CHF 173 million in Q3 2010.

Outlook: Clariant expects a similar trading environment to the third quarter until year-end 2011, characterized by further softening demand, volatile currencies and stable raw material costs. For the full-year 2011, Clariant confirms its guidance, with sales between CHF 7.0 and 7.2 billion and an EBITDA margin of 12.8% to 13.2%.

CEO Hariolf Kottmann commented: “In the first nine months of 2011, Clariant has further progressed in making the achievements of the last two years sustainable, despite strong headwinds from currency markets and a softening global economy. We have managed to improve underlying profitability by consistently applying strict performance management while at the same time shifting management focus toward profitable growth. From the solid base achieved – both operationally and financially – we will move forward in our strategy implementation and continue to transform Clariant in the coming years to achieve our ambitious 2015 targets.”

Clariant Q3, 2011 Performance

Muttenz, 31 October 2011 – Clariant, a world leader in specialty chemicals, today announced sales of CHF 1.865 billion in the third quarter 2011, compared to CHF 1.709 billion in the previous year. This includes Süd-Chemie (SC) sales of CHF 356 million. In local currencies, sales growth amounted to 25%. In Swiss francs, year-on-year sales were only 9% higher as the Swiss franc continued to strengthen against most major currencies especially in the first half of the third quarter.

Sales growth was driven by higher prices and the acquisition of Süd-Chemie. The less cyclical Business Units Additives, Catalysis & Energy, Functional Materials, Industrial & Consumer Specialties and Oil & Mining Services – accounting for roughly 50% of group sales – showed the most dynamic growth. By contrast, the slowdown in demand in the more cyclical businesses already observed in June has spread along the plastics value chain and into the coatings business. Regionally, the traditional markets of Europe and North America outpaced Asia/Pacific, Latin America and the Middle East & Africa. In the emerging markets a slow-down in the dynamic growth of the last few quarters has been observed.

Excluding Süd-Chemie, sales increased by 5%, driven by a 9% increase in sales prices, while volumes decreased 4% compared to the previous-year period as a result of a combination of softening demand in some businesses and the deliberate loss of unprofitable contracts.

The gross margin fell to 26.1% from 27.9% a year ago, mainly due to the negative currency impact and volume effects. In a slower global economic growth environment, commodity prices stabilized during the quarter. As a consequence, raw material costs remained flat compared to the second quarter 2011, but were 13% higher than in the previous-year period. As expected, increased raw material costs were fully absorbed by higher sales prices, both year-on-year and sequentially.

EBITDA before exceptional items fell to CHF 216 million (margin 11.6%) from CHF 232 million (margin 13.6%) a year ago. This was mainly the result of unfavorable currency developments which peaked in the third quarter. Operating profit (EBIT) before exceptional items stood at CHF 144 million (margin 7.7%) compared to CHF 182 million (margin 10.6%) in the third quarter of 2010. Both EBITDA and EBIT before exceptional items were negatively impacted by CHF 73 million (EBITDA) and CHF 63 million (EBIT) respectively from currencies. Net income was CHF 81 million compared to CHF 109 million in the previous-year period.

Cash flow from operations improved to CHF 105 million, below last year’s CHF 173 million, but clearly above the CHF –101 million reported in the second quarter of 2011. Due to lower sales, Net Working Capital as a percentage of sales increased to 21.3% compared to 19.7% in the previous-year period, but is on track to meet the year-end 2011 target of below 20% of sales.

Due to the acquisition of Süd-Chemie, net debt increased to CHF 1 812 million from CHF 126 million at year-end, resulting in a gearing (net debt divided by equity) of 62% at the end of the third quarter of 2011. The cash position was strong with CHF 1.029 billion in cash and cash equivalents at quarter-end. The extension of the maturity profile is underway with the issuance of bonds totaling CHF 300 million in the Swiss francs market since May. After the reporting period, another EUR 365 million in certificates of indebtedness with terms of three years and four and a half years have been raised in October.

Süd-Chemie delivers, integration on track In the first full quarter of consolidation into Clariant, the two new Süd-Chemie Business Units – Catalysis & Energy and Functional Materials – developed according to plan, with the Catalysts business picking-up in the third quarter as expected. Catalysis & Energy reported an EBITDA
before exceptionals of CHF 41 million (margin 21.6%), and Functional Materials CHF 18 million (margin 10.8%).

The integration of Süd-Chemie is progressing as planned with all project teams fully operational. Based on current insights and integration experience, the anticipated EUR 75-95 million EBITDA improvements to 2013 are confirmed. Integration synergies and functional excellence efforts are expected to lead to redundancy for some 700 FTE worldwide, primarily in G&A functions but also from improvement measures in production. The implementation of the measures is expected in the
timeframe from 2012 to 2014 with a focus on 2012/13 once the squeeze-out becomes effective.

Going forward, the focus will be on the continued delivery of the business objectives of Süd-Chemie while progressing with the integration and the squeeze-out process.

Outlook 2011
At the beginning of 2011, Clariant shifted its focus from restructuring to continuous improvement and profitable growth. While the continuous improvement initiative “Clariant Excellence” will make the competitive cost basis sustainable, the company is now focusing on creating value by investing in future profitable growth.

In the fourth quarter, Clariant expects the general slow-down in economic activity to continue, with clear signs of further weakness in demand in some regions and industries, especially in Europe. Exchange rates for the major currencies are expected to remain volatile. Commodity prices look set to stabilize at the level of the third quarter, leading to an increase in raw material costs in the mid-teens in 2011 compared to 2010.

For 2011, Clariant – including eight months of consolidated Süd-Chemie figures – expects sales in the range of CHF 7.0 to 7.2 billion and an EBITDA margin before exceptional items of 12.8% to 13.2%.

Clariant – Exactly your chemistry.
Clariant is a global leader in the field of specialty chemicals. Strong business relationships, commitment to outstanding service and wide-ranging application know-how make Clariant a preferred partner for its customers.
Clariant, which is represented on five continents with over 100 group companies, employs around 16,200 people as of year-end 2010. Head-quartered in Muttenz near Basel, Switzerland, it generated sales of CHF 7.1 billion in 2010. Clariant is organized into 12 Business Units: Additives; Catalysis & Energy; Detergents & Intermediates; Emulsions; Functional Materials; Industrial & Consumer Specialties; Leather Services; Masterbatches; Oil & Mining Services; Paper Specialties; Pigments; and Textile Chemicals. Clariant is committed to sustainable growth, which is derived from its own innovative strength. Clariant’s world-class products and services play a key role in its customers’ manufacturing processes and add value to their end products. The company’s success is based on the know-how of its people and their ability to identify new customer needs at an early stage and to work together with customers to develop innovative, efficient solutions.
www.clariant.com

EMG
Paulien Boumans
Lelyweg 6
4612 PS
Bergen op Zoom
The Netherlands
0031164317015

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Operationally on track, Süd-Chemie on target here

News-ID: 198454 • Views:

More Releases from Clariant International Ltd

Clariant Innovation Center Cornerstone Laid at Industriepark Höchst for 500 New …
- Finance Minister Thomas Schäfer: Investment brings major benefits - Christian Kohlpaintner: 100 million euros to provide optimal conditions for sustainable, successful research Muttenz / Frankfurt, February 29, 2012 - The cornerstone of the new 100-million-euro Clariant Innovation Center was officially laid during a ceremony today at the Industriepark Höchst in Frankfurt. Attending the event were Hessen State Finance Minister Thomas Schäfer; Clariant Executive Committee member Christian Kohlpaintner; and Ulrich Ott, Managing
Clariant successfully issues EUR 500 million Eurobond
Muttenz, January 17, 2012 – Today, Clariant successfully priced an Eurobond transaction of EUR 500 million with a tenor of 5 years, issued by Clariant Finance (Luxembourg) S.A. and guaranteed by Clariant Ltd. The fixed rate notes with a minimum denomination of EUR 100,000 and a final coupon of 5 ⅝ % p.a. are maturing on January 24, 2017. The orderbook was significantly oversubscribed on the back of strong investor demand.
Clariant’s EasyWhite Tan process — leaner, cleaner and safer
Clariant’s EasyWhite Tan process — leaner, cleaner and safer
Muttenz, November 14, 2011 - Specialty chemicals expert Clariant is offering tanners the first viable scientific and commercial option to traditional tanning methods in some 125 years with the global launch of EasyWhite Tan. The first major advance since the advent of chrome-based tanning revolutionized the industry back in the late 1800s, the new EasyWhite Tan process delivers a ground-breaking alternative to conventional methods based on metals (such as chrome, which
Clariant Strengthens Presence in China with Opening of its First Ethoxylation Pl …
Muttenz/ Shanghai, November 1, 2011 - Clariant, the Swiss leading specialty chemicals company, announced the inauguration of its ethoxylation plant in Daya Bay at Huizhou, Guangdong Province, China today. The plant not only benefits customers with local production but also brings global know-how and technology in product development to the local market. Construction of the plant is pivotal to Clariant’s global strategy on further developing the emerging markets. The plant in

All 5 Releases


More Releases for CHF

Congestive Heart Failure (CHF) Treatment Devices Market Revenue Sizing Outlook A …
Allied Market Research added new research on Global Congestive Heart Failure (CHF) Treatment Devices Market- Global Opportunity Analysis and Industry Forecast, 2022-2030. The Congestive Heart Failure (CHF) Treatment Devices market explores comprehensive study on various segments like size, share, development, innovation, sales and overall growth of major players. The research is based on primary and secondary data sources and it consists both qualitative and quantitative detailing. Some of the key
Chronic Heart Failure (CHF) Drugs Industry Outlook and Forecast 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Chronic Heart Failure (CHF) Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Chronic Heart Failure (CHF) Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). GLOBAL INFO RESEARCH has lately published a new report titled, *Global Chronic Heart Failure (CHF) Drugs Market 2020 by Manufacturers, Regions,
Screening Eagle raises CHF 55 million to protect the built world
Screening Eagle Technologies (SET), a cloud-based technology platform connecting sensors, software, and data for intelligent inspection of assets and infrastructure, is pleased to announce it has raised CHF 55 million in its first institutional round of equity funding. Switzerland - April 3, 2020 -- Screening Eagle is on a mission to protect the built world. Massive economic value is at risk from aging global infrastructure and construction birth defects in
Global Congestive Heart Failure (CHF) Market Status, Analysis, Growth Factor, Ap …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Congestive Heart Failure (CHF) Market Research Report 2018” provides an in-depth analysis of the Congestive Heart Failure (CHF) with the forecast of market size and growth. The analysis includes addressable market, market by volume, and market share by business type and by segment (external and in-house).The research study examines the
Congestive Heart Failure (CHF) Treatment Devices Market Latest Trends by 2024
Congestive Heart Failure (CHF) is a chronic condition of a body, which adversely affects the pumping efficiency of the cardiac muscles and the heart. It occurs due to accretion of fluid around the heart that may contribute towards ineffective pumping of the heart. This condition may result in shortness of breathing, swelling and weakness. Left-sided CHF is the more commonly noted than right-sided CHF. Left-sided CHF occurs due to
Congestive Heart Failure (CHF) Treatment Devices Market: Report Scope and Market …
Congestive Heart Failure (CHF) is a chronic condition of a body, which adversely affects the pumping efficiency of the cardiac muscles and the heart. It occurs due to accretion of fluid around the heart that may contribute towards ineffective pumping of the heart. This condition may result in shortness of breathing, swelling and weakness. Left-sided CHF is the more commonly noted than right-sided CHF. Left-sided CHF occurs due to